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                  Figure 1.  (A) Steady –state granulopoeisis. (B) Emergency granulopoeisis.   
 
 
 
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
 
 
Methods 
A B 
Cell Culture and Treatment 
Sample Collection and Analysis  
U937 cells were plated onto three 12-well plates. Each plate 
corresponded to a time point of 24 hours, 48 hours, and 72 
hours. 5.0x105  cells were placed into each well. Treatments 
used were 20, 40 ng, 50ng, 60ng and 80ng of IL-1β, and an 
untreated control was used for each plate.  
 
At 24 hours, 48 hours, and 72 hours, cells were washed, 
collected, and placed in 400սL of Trizol.  RNA extraction was 
performed, and cDNA was made using RNA, nuclease-free 
water, and iScript reverse transcriptase mix. A  qPCR was 
then run using FANCC, BRCA1 and GAPDH probes to 
measure FANCC and BRCA1 expression.  
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Treatment of U937 cells with different concentrations of IL1-β 
Figure 3. Relative expression of 
BRCA1 and FANCC in U937 cells 
post (A) 20 ng IL-1β treatment. (B) 
40 ng IL-1β treatment. (C) 50 ng 
IL-1β treatment. (D) 60 ng IL-1β 
treatment. (E) 80 ng IL-1β 
treatment. 
BRCA1 mutation carriers face high risks of breast and ovarian cancer due 
to mutations in DNA repair genes. Typical treatments of these cancers rely 
on killing cells by mechanisms such as induction of DNA damage, altering 
cell cycle checkpoints, or cell division. A study has examined BRCA1 
mutation carriers treated for breast cancer and found evidence of 
neutropenia as patients experienced decreases in their blood counts.1 
Neutrophils are a key cell type in the innate immune system; they serve as 
the first line of defense as they are recruited to respective sites of infection.2 
However, they are short lived; and thus, they need to be continuously 
generated in steady-state conditions from hematopoietic stem cells and 
progenitor cells in bone marrow to ensure containment of invading 
pathogens. When an infectious or inflammatory challenge presents itself, 
and neutrophils are used up in large quantities, the hematopoietic system 
has to rapidly adapt to increased demands by switching from steady-state 
granulopoeisis to emergency granulopoeisis (Fig, 1).3 Here, we investigate 
whether deficiency in BRCA1 impairs emergency granulopoeisis. 
It has been shown that the Fanconi pathway contributes to genomic stability 
during emergency granulopoeisis, and increased Fanconi  C (Fancc) 
expression contributes to emergency granulopoeisis. Fancc mRNA 
expression in myeloid leukemia cells, U937, increased when cells were 
stably transfected with an IRF8 control vector and  treated with IL-1β.4   The 
IRF8 vector is essential  in activating phagocyte effector genes during the 
innate immune response, and ultimately activates the gene coding for 
Fancc. Since FANCC is downstream of the pathway to BRCA1 gene 
expression (Fig. 2), we hypothesize that treatment of U937 cells  with IL-1β 
will lead to  increased expression of BRCA1.  
Figure 2.  Fanconi pathway participates in DNA repair through translesional synthesis 
(TLS). Fanconi core complex proteins (Fanconi A, B, C, E, F, G, M, N) interact with Polζ 
and Rev1 to activate BRCA1 and FANCJ. Deficiency of any Fanconi protein causes 
defective DNA cross-link repair4.  
 FANCC expression in U937 cells  does not significantly change over time with 
increasing concentrations of IL-1β. 
 
 FANCC expression was lowest at 48 hours post IL-1β treatment. 
 
 BRCA1 expression had a greater decrease at  20 ng to 50 ng IL-1β. 
 
 It appears that the general trend for both FANCC and BRCA1 expression is 
different than what has previously been reported (4).  
 
 Transfect U937 cells with an IRF8 vector before treating with IL-1β, and assay 
for FANCC expression as shown in previous literature.  
 
 Assay for FANCC expression in U937 PMA treated cells to investigate 
emergency granulopoeisis in macrophage-like cells and mouse bone marrow 
derived macrophages. 
  
 Assay for proteins involved in BRCA1 activation including, but not limited to 
RAD51, RNA pol. II, BARD1, and p53 to examine additional components to 
the BRCA1 gene.  
 
 Assay for HIP1, a protein studied in the lab and shown to have  no change in 
expression following BRCA1 over-expression , for use as an additional control. 
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